echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The Lancet's invalid research paper on hydroxychloroquine was withdrawn

    The Lancet's invalid research paper on hydroxychloroquine was withdrawn

    • Last Update: 2020-11-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    BEIJING, June 5 (Xinhua Chinese) -- A research paper on the ineffective treatment of new crown patients by the drug hydroxychloroquine was withdrawn from the Lancet medical journal on The Lancet on Sunday after doctors and scientists questioned the validity of the data.
    previous study concluded that patients taking the antimalarial drug hydroxychloroquine had a higher risk of death than those who did not, leading some researchers to halt clinical trials.
    study, led by Mandeep Mehla of Harvard Medical School, was published in late May. But they withdrew the study from The Lancet because independent peer reviewers could not access the data used for analysis.
    in this collaboration, we all participate in this collaboration and sincerely contribute during this very period of the new crown pandemic," the authors wrote in a statement on June 4. "We apologize for any embarrassment or inconvenience this may cause, and we apologize to you, your editors, and your journal readers."
    the study used data from health care analytics firm Surgisphere Corporation, which hospitalized more than 96,000 new crown patients in 671 hospitals on six continents, the Associated Press reported. However, the company told peer reviewers that it would not disclose the full data set used for research because it would violate customer agreements and confidentiality requirements.
    Surgisphere Corporation is one of the study's co-authors, Sapan Desai. Desai did not sign the withdrawal application with three other co-authors, the report said.
    The Lancet wrote in a statement that it "takes scientific integrity very seriously" and that "there are many outstanding issues regarding Surgisphere and the data allegedly included in this study." The
    comes after President Trump under a two-week hydroxychloroquine treatment after one of his drivers tested positive for a new crown. But another previously published study showed that the drug was not effective in preventing new crowns.
    study of 368 patients published in the New England Journal of Medicine in April found that the two main outcomes of new crown patients treated with hydroxychloroquine were either death or critical illness, requiring a ventilator.
    , although not rigorous, includes trials led by the National Institutes of Health and the World Health Organization, and randomized trials of hydroxychloroquine are still ongoing.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.